FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.
What happened
FDA inspected Kath Khemicals' drug manufacturing facility in Macomb, Michigan from March 31 to April 3, 2025. Investigators found the company released over-the-counter antibacterial hand soap and handwash batches without finished-product testing for identity, strength, and microorganisms, and without adequate identity testing of incoming glycerin for diethylene glycol (DEG) and ethylene glycol (EG). FDA also found no adequate stability program and an incomplete quality unit and batch records, and called the company's April 15, 2025 response inadequate.
What FDA found
The company did not test each batch of finished drug product for identity and strength of active ingredients, or for harmful microorganisms, before release.
21 CFR 211.165(a) and 211.165(b)The company did not perform at least one identity test on each incoming component; its glycerin test did not check for DEG or EG, which have caused fatal poisonings.
21 CFR 211.84(d)(1)The company had no adequate stability program to show its products stay within specifications through the 12-month expiration period; reserve samples were only checked visually for color.
21 CFR 211.166(a)The quality control unit did not oversee manufacturing: there were no written procedures for investigations, change controls, corrective actions, recalls, reprocessing, or batch rejection, and a batch record was incomplete.
21 CFR 211.22
What FDA wants
FDA asks the company to respond in writing within 15 working days describing corrections and preventive actions, including a full testing plan, glycerin and component testing, a stability program, and a quality unit remediation plan, and says a qualified consultant should be engaged.
Who should pay attention
- retailers and distributors that stock store-brand antibacterial hand soaps
- contract manufacturers and packagers of OTC topical drug products
- suppliers of glycerin and other high-risk drug components
This is a summary. Read the original letter on fda.gov.